St. Jude Children’s Research Hospital shared a post on LinkedIn:
“Cancer Immunotherapy Month, observed each June, highlights progress in harnessing the immune system to treat cancer. At St. Jude, that progress spans decades and has been pivotal in advancing immunotherapy treatments for pediatric cancers.
St. Jude established the Division of Immunology in 1975 and the Bone Marrow Transplant Program in 1982, which is now called the Bone Marrow Transplantation and Cellular Therapy Program. Together, these efforts built the foundation and infrastructure to better understand the immune system, and develop therapies based on new scientific discoveries.
The St. Jude legacy as a leader in immunology and immunotherapy includes the leadership of Nobel Prize recipient and emeritus faculty member Peter Doherty, PhD, whose earlier discoveries on how the immune system distinguishes virus-infected cells from normal cells transformed modern immunology. That legacy continues through the Center of Excellence for Pediatric Immuno-Oncology (CEPIO), co-led by Hongbo Chi, PhD, Department of Immunology chair, and Stephen Gottschalk, MD, Department of Bone Marrow Transplantation and Cellular Therapy chair.
Today, coordinated research through CEPIO builds on the legacy of immunotherapy research at St. Jude by bringing together discovery, translational science and collaboration to advance new therapies.”
To which Stephen Gottschalk, Chair, Department of Bone Transplant and Cellular Therapy, added:
“Would like to thank my mentors – Clio Rooney, Helen Heslop and Malcolm Brenner, who pioneered the use of EBV-specific T cells ~30 years ago at St Jude!”
Other articles about St. Jude Children’s Research Hospital and Stephen Gottschalk on OncoDaily.